GO:0140297 DNA-binding transcription factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140297 describes the molecular function of binding to a DNA-binding transcription factor, a protein that recognizes specific DNA sequences to modulate transcription [1,3].
• This activity is central to gene regulation, as it enables transcription factors to interact with cofactors, modifiers, and other regulatory proteins [3,6].
• Key proteins involved include AP-2, Sp1, TBP-associated factors, TFIIA, TFIIIC, and PIT1, each with distinct DNA-binding and interaction properties [3,5,6,7,8].
• Dysregulation of DNA-binding transcription factor binding is implicated in cancer, developmental disorders, and viral infections [2,7].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal roles of these interactions [3,6].
• EDITGENE provides comprehensive services to study GO:0140297, from cell model generation to CRISPR library screening and bioinformatics.
Description
DNA-binding transcription factor binding (GO:0140297) is a molecular function that enables a protein to selectively interact with a DNA-binding transcription factor, a protein that itself recognizes specific DNA sequences to regulate transcription [1,3]. This binding event is a cornerstone of gene regulation, as it allows transcription factors to recruit coactivators, corepressors, and chromatin-modifying enzymes, thereby modulating the expression of target genes [3,6]. Understanding this function is critical for deciphering transcriptional networks in development, homeostasis, and disease. The term encompasses interactions with both activating and repressing transcription factors, reflecting its broad role in both positive and negative gene regulation [3,5]. Researchers study GO:0140297 to identify novel regulatory partners, to map interaction interfaces, and to develop therapeutics targeting aberrant transcription factor activity [2,6].
DNA-binding transcription factor binding At A Glance
| GO ID | GO:0140297 |
|---|---|
| GO term | DNA-binding transcription factor binding |
| Ontology | molecular_function |
| Synonym | activating transcription factor binding; repressing transcription factor binding; transcription activator binding |
| Major function | Binding to a DNA-binding transcription factor to modulate transcription |
| Definition source | QuickGO |
| Related processes | Transcription regulation, signal transduction, development |
| Example proteins | AP-2, Sp1, TFIIA, TFIIIC, PIT1 |
What Is GO:0140297?
GO:0140297 is defined as the binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription. This function is distinct from sequence-specific DNA binding itself; it describes the protein-protein interaction between a binding partner and a transcription factor that is already capable of DNA recognition.
Why Is DNA-binding transcription factor binding Important in Cell Biology?
GO:0140297 is fundamental to understanding how transcription factors communicate with the broader regulatory machinery. Many transcription factors do not act alone; they require binding partners to stabilize DNA occupancy, recruit cofactors, or modify chromatin [3,5]. Disruption of these interactions can lead to profound changes in gene expression programs, contributing to diseases such as cancer, hormonal disorders, and viral pathogenesis [2,7]. Thus, studying this function provides mechanistic insights into normal physiology and disease, and offers potential targets for therapeutic intervention [6,8].
• Enables combinatorial control of gene expression by allowing transcription factors to integrate signals from multiple pathways.
• Facilitates recruitment of coactivators and corepressors, thereby determining the outcome of transcriptional regulation.
• Plays a role in developmental processes, as exemplified by PIT1 abnormalities leading to combined pituitary hormone deficiency.
• Is exploited by viruses, such as adenovirus, to hijack host transcriptional machinery.
• Contributes to cancer when interactions are deregulated, affecting oncogene and tumor suppressor expression.
• Provides a basis for understanding how sequence-specific transcription factors achieve target gene specificity.
• Offers opportunities for drug discovery targeting protein-protein interactions.
• Is essential for interpreting non-coding genetic variants that may affect transcription factor binding.
• Underpins the function of general transcription factors like TFIIA and TFIIIC in basal transcription [5,8].
• Can be studied using advanced CRISPR and biochemical methods to map interaction networks [3,6].
Molecular Mechanism of DNA-binding transcription factor binding
Recognition and Binding to the Transcription Factor
In simple terms: One protein grabs onto a transcription factor that is already sitting on DNA.
The binding event typically involves a specific interface on the DNA-binding transcription factor, often outside its DNA-binding domain, allowing the partner protein to dock without displacing the factor from DNA. For example, the human transcription factor AP-2 interacts with various cofactors through its activation domain, which is distinct from its DNA-binding domain. Similarly, the honeybee Mblk-1 protein exhibits DNA-binding properties and likely interacts with other transcription factors to regulate gene expression. This step is crucial for forming higher-order transcriptional complexes.
Stabilization of the Transcription Factor-DNA Complex
In simple terms: The binding partner helps the transcription factor stay on DNA longer.
Binding to a partner can stabilize the transcription factor's interaction with DNA, as seen with TFIIA, which derepresses TBP-associated factor inhibition of TBP-DNA binding. This stabilization ensures sustained transcriptional activation or repression. In the case of TFIIIC, subunit interactions are critical for its function, and disruption of these interactions impairs DNA binding. Thus, GO:0140297 often involves allosteric effects that enhance DNA occupancy.
Recruitment of Coactivators and Corepressors
In simple terms: The binding partner brings in other proteins that turn genes on or off.
Once bound to a DNA-binding transcription factor, the partner protein can recruit additional cofactors. For instance, Sp1 recruits TAFs and other components of the basal transcription machinery through protein-protein interactions. Similarly, the adenovirus DNA replication protein may interact with host transcription factors to facilitate viral replication. This recruitment leads to chromatin modification, histone acetylation, or direct activation of RNA polymerase II.
Modulation of Transcriptional Output
In simple terms: The final result is a change in how much a gene is expressed.
The ultimate consequence of GO:0140297 is modulation of transcription, either activation or repression. For example, PIT1 abnormalities affect the transcription of growth hormone and prolactin genes, leading to hormonal deficiencies. The phage T4 MotA protein contains a novel DNA-binding motif that specifically recognizes modified DNA, illustrating how transcription factor binding can be modulated by DNA modifications. Thus, this function integrates signals to fine-tune gene expression.
Regulation of the Binding Interaction
In simple terms: The interaction itself can be turned on or off by cellular signals.
The binding of proteins to DNA-binding transcription factors is often regulated by post-translational modifications, such as phosphorylation, which can alter affinity or localization. For instance, the activity of AP-2 is modulated by phosphorylation. Additionally, competition with other binding partners or changes in expression levels can dynamically regulate these interactions, as seen in the poliovirus 3C protease cleavage of TFIIIC subunits, which disrupts its function.
Key Genes Involved in GO:0140297 DNA-binding transcription factor binding
The following genes and proteins are representative examples of DNA-binding transcription factors and their binding partners that participate in GO:0140297.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AP-2 | DNA-binding transcription factor; interacts with cofactors | Model for studying activation domain interactions |
| Sp1 | DNA-binding transcription factor; recruits TAFs | Prototype for understanding GC-box regulation |
| TBP | TATA-binding protein; interacts with TFIIA | Central to basal transcription |
| TFIIA | General transcription factor; stabilizes TBP-DNA | Derepresses TAF inhibition |
| TFIIIC | General transcription factor; subunit interactions | Dissected by poliovirus protease |
| PIT1 | Pituitary-specific transcription factor | Mutations cause combined pituitary hormone deficiency |
| Mblk-1 | Honeybee transcription factor | Model for DNA-binding properties |
| MotA | Phage T4 transcription factor | Recognizes modified DNA |
| Adenovirus E1A | Viral protein; interacts with host transcription factors | Studied in adenovirus DNA replication |
| TAF1 | TBP-associated factor; inhibited by TFIIA | Regulates TBP-DNA binding |
| GATA1 | DNA-binding transcription factor; interacts with cofactors | Implicated in hematopoiesis (generic) |
| MYC | DNA-binding transcription factor; interacts with cofactors | Oncogenic transcription factor (generic) |
| TP53 | DNA-binding transcription factor; interacts with cofactors | Tumor suppressor (generic) |
| NF-kB | DNA-binding transcription factor; interacts with cofactors | Inflammation and immunity (generic) |
| STAT3 | DNA-binding transcription factor; interacts with cofactors | Signal transduction (generic) |
| FOXP3 | DNA-binding transcription factor; interacts with cofactors | Regulatory T cell development (generic) |
| CTCF | DNA-binding transcription factor; interacts with cofactors | Chromatin architecture (generic) |
How Is DNA-binding transcription factor binding Regulated?
The binding of proteins to DNA-binding transcription factors is regulated at multiple levels. Post-translational modifications, such as phosphorylation, can modulate the affinity or specificity of the interaction. For example, the activity of AP-2 is regulated by phosphorylation, affecting its interaction with cofactors. Additionally, the availability of binding partners can be controlled by expression levels, degradation, or sequestration. Viral proteins, such as poliovirus 3C protease, can cleave transcription factors like TFIIIC, thereby disrupting their interactions and function. Furthermore, the DNA-binding transcription factor itself can undergo conformational changes upon DNA binding, exposing or hiding interaction surfaces. These regulatory mechanisms ensure that GO:0140297 is dynamically controlled in response to cellular signals.
DNA-binding transcription factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIT1 | Combined pituitary hormone deficiency | Knockout mouse or patient-derived iPSCs |
| AP-2 | Cancer (melanoma, breast) | Overexpression and knockout cell lines |
| Sp1 | Cancer (pancreatic, gastric) | CRISPR knockout and point mutation |
| TFIIIC | Viral pathogenesis (poliovirus) | Knockout and cleavage-resistant knock-in |
| Adenovirus E1A | Viral replication | Infection models with knockout cells |
Cancer
Deregulation of DNA-binding transcription factor binding can lead to aberrant expression of oncogenes or tumor suppressors. For instance, AP-2 transcription factors are involved in cancer progression, and their interactions with cofactors modulate target gene expression. Similarly, Sp1 is overexpressed in many cancers and its binding to TAFs is critical for its oncogenic functions. Targeting these interactions is a potential therapeutic strategy.
Developmental and Hormonal Disorders
Mutations in PIT1, a DNA-binding transcription factor, cause combined pituitary hormone deficiency, highlighting the importance of its interactions with cofactors for normal development. Disruption of these binding events can lead to hormonal imbalances and growth defects.
Viral Infections
Viruses often hijack host transcription factor binding to promote their replication. Adenovirus proteins interact with host transcription factors to facilitate viral DNA replication. Similarly, poliovirus protease cleaves TFIIIC, disrupting host transcription and aiding viral pathogenesis.
From DNA-binding transcription factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of the binding partner affect transcription factor occupancy? | Knockout cell line |
| Does a specific point mutation disrupt the interaction? | Point mutation knock-in |
| Can a tagged version of the protein be used for pulldown? | Tagged knock-in |
| Does overexpression of the partner enhance transcription? | Overexpression cell line |
| Which domains are required for binding? | Deletion mutants via CRISPR |
| Can the interaction be disrupted by a small molecule? | Knock-in with reporter and drug treatment |
How to Study the DNA-binding transcription factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide binding sites of transcription factors | Mapping regulatory elements |
| Co-IP | Protein-protein interactions | Validating binding partners |
| EMSA | DNA-binding activity | Assessing complex formation |
| CRISPR screen | Genes affecting a phenotype | Identifying regulators of transcription |
| Proteomics | Protein abundance and modifications | Quantifying interaction networks |
| RNA-seq | Transcriptional changes | Measuring impact on gene expression |
| Reporter assays | Transcriptional activity | Testing regulatory elements |
Chromatin Immunoprecipitation (ChIP)
ChIP allows the detection of DNA-binding transcription factors on chromatin. When combined with antibodies against the binding partner, it can reveal whether the partner is recruited to specific genomic loci. This method is essential for mapping the genomic binding sites of transcription factors and their interacting proteins.
Co-immunoprecipitation (Co-IP) and Pull-down
Co-IP and pull-down assays are used to detect protein-protein interactions between DNA-binding transcription factors and their partners. For example, the interaction between TFIIA and TBP was demonstrated using such methods. These techniques are fundamental for validating binding events in vitro and in vivo.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA measures the ability of a protein to bind to a specific DNA sequence. It can be used to assess whether a binding partner stabilizes the transcription factor-DNA complex. This method is particularly useful for studying the DNA-binding properties of transcription factors like Mblk-1.
CRISPR-Based Genetic Screens
CRISPR knockout or activation screens can identify genes that regulate DNA-binding transcription factor binding. For instance, a screen for modifiers of AP-2 activity could reveal novel cofactors. These screens are powerful for unbiased discovery of interaction partners.
How CRISPR Can Be Used to Study GO:0140297 DNA-binding transcription factor binding
Knockout
CRISPR knockout of a gene encoding a DNA-binding transcription factor or its binding partner can abolish the interaction, revealing its role in transcription. For example, knocking out AP-2 would disrupt its interactions with cofactors and affect target gene expression. Knockout models are essential for loss-of-function studies.
Point Mutation
Introducing point mutations in the interaction interface can specifically disrupt binding without affecting other functions. For instance, mutating residues in the activation domain of AP-2 could prevent cofactor recruitment. This approach provides fine-grained mechanistic insights.
Knock-in
Knock-in of a tagged version of the transcription factor allows for affinity purification and genomic mapping. For example, a FLAG-tagged Sp1 could be used to identify its binding partners. Knock-in models are valuable for studying endogenous complexes.
Overexpression
Overexpression of a DNA-binding transcription factor or its partner can enhance or disrupt transcriptional programs. For example, overexpressing Sp1 may titrate out limiting cofactors, leading to dominant-negative effects. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports DNA-binding transcription factor binding Research
Researchers studying DNA-binding transcription factor binding-related genes often need to determine whether a candidate gene is causally involved in a specific transcriptional program or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of interactions and mechanisms.
Contact EDITGENE today to design your custom CRISPR model for DNA-binding transcription factor binding research.
Frequently Asked Questions About DNA-binding transcription factor binding
What is GO:0140297?
GO:0140297 is a Gene Ontology molecular function term that describes the binding to a DNA-binding transcription factor, a protein that interacts with specific DNA sequences to modulate transcription.
What genes are involved in DNA-binding transcription factor binding?
Genes encoding transcription factors such as AP-2, Sp1, TBP, TFIIA, TFIIIC, and PIT1 are involved, as well as their binding partners [3,5,6,7,8].
How is DNA-binding transcription factor binding studied?
Common methods include ChIP, Co-IP, EMSA, CRISPR screens, and proteomics [1,3,5].
Why is DNA-binding transcription factor binding important?
It is crucial for gene regulation, development, and disease; disruptions can lead to cancer, hormonal disorders, and viral infections [2,3,7].
What diseases are associated with defects in DNA-binding transcription factor binding?
Diseases include combined pituitary hormone deficiency, cancer, and viral pathogenesis [2,7].
Can CRISPR be used to study DNA-binding transcription factor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect these interactions [3,6].
What are the synonyms for GO:0140297?
Synonyms include activating transcription factor binding, repressing transcription factor binding, and transcription activator binding.
What is the difference between DNA binding and DNA-binding transcription factor binding?
DNA binding refers to direct interaction with DNA, while DNA-binding transcription factor binding refers to protein-protein interaction with a transcription factor that itself binds DNA.
How does EDITGENE support research on DNA-binding transcription factor binding?
EDITGENE provides custom CRISPR cell models, library screening, and bioinformatics services to study these interactions.
What model systems are suitable for studying DNA-binding transcription factor binding?
Knockout, point mutation, knock-in, and overexpression cell lines are commonly used, as well as animal models [3,7].
Conclusion
GO:0140297, DNA-binding transcription factor binding, is a fundamental molecular function that underpins transcriptional regulation. Through interactions with DNA-binding transcription factors, partner proteins modulate gene expression programs critical for development, homeostasis, and disease. Understanding these interactions requires a combination of biochemical, genomic, and CRISPR-based approaches. EDITGENE offers a comprehensive toolkit to generate precisely engineered cell models and perform functional screens, empowering researchers to uncover the mechanisms and therapeutic potential of this important function.
References
- 1. Park JM et al.. 2002. DNA-binding properties of Mblk-1, a putative transcription factor from the honeybee.. Biochem Biophys Res Commun 291(1):23-8 PMID: 11829456
- 2. Liu H et al.. 2003. Adenovirus DNA replication.. Curr Top Microbiol Immunol 272:131-64 PMID: 12747549
- 3. Williams T et al.. 1991. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2.. Genes Dev 5(4):670-82 PMID: 2010091
- 4. Cuypers MG et al.. 2018. The phage T4 MotA transcription factor contains a novel DNA binding motif that specifically recognizes modified DNA.. Nucleic Acids Res 46(10):5308-5318 PMID: 29718457
- 5. Ozer J et al.. 1998. Transcription factor IIA derepresses TATA-binding protein (TBP)-associated factor inhibition of TBP-DNA binding.. J Biol Chem 273(23):14293-300 PMID: 9603936
- 6. Kadonaga JT et al.. 1987. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain.. Cell 51(6):1079-90 PMID: 3319186
- 7. Tatsumi K et al.. 1999. PIT1 abnormality.. Growth Horm IGF Res 9 Suppl B:18-22; discussion 23 PMID: 10549301
- 8. Shen Y et al.. 1996. DNA binding domain and subunit interactions of transcription factor IIIC revealed by dissection with poliovirus 3C protease.. Mol Cell Biol 16(8):4163-71 PMID: 8754815
